Company record
Enveda
Updated October 19, 2026 · Presspool
Enveda is a clinical-stage biotechnology company that uses AI to identify molecules made by living organisms and develop them into oral medicines. enveda.com
Funding
- $311 million Series E, announced September 23, 2026. Led by Catalio Capital Management. Listed in the AI startup funding roster for September 21–26, 2026. Sources: Enveda, TechCrunch.
Of the 6 Series E rounds with exactly stated amounts in dollars on Presspool's weekly rosters since September 21, 2026, Enveda's $311 million is the 3rd largest; their median is $281 million.
Whether AI names Enveda
- Machine Relations Index: Not cited in any Machine Relations Index answer, May 10, 2026 to October 18, 2026.
Related records
Closest rounds in the roster for September 21–26, 2026: Snorkel AI ($350 million Series E, September 22, 2026), Heidi ($340 million Series C plus growth investment, September 22, 2026), Island ($400 million Series F, September 24, 2026), Cyera ($400 million Series G extension, September 22, 2026), ASI ($225 million, round type not disclosed, September 24, 2026), TEKEVER ($580 million Series D, September 23, 2026).